Research and Markets: Key Findings from Treatment Algorithms: Multiple Sclerosis

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/ts4pv3/key_findings_from) has announced the addition of Decision Resources, Inc's new report "Key Findings from Treatment Algorithms: Multiple Sclerosis" to their offering.

Until recently, the MS market comprised a stable mix of time-tested disease-modifying therapies with established roles in treatment several interferon-beta (IFN-) products, glatiramer acetate (Teva's Copaxone), and natalizumab (Biogen Idec/Elan's Tysabri). Today, however, the MS market stands at the brink of transformation.

The 2010 launch of fingolimod (Novartis/Mitsubishi Tanabe Pharma's Gilenya)the first orally administered disease-modifying drug for MSmarks the beginning of a new era in MS treatment that will feature enhanced treatment choice, increasingly complex decision-making for prescribers, and an invigorated push toward individualized treatment.

In the coming years, neurologists will strive to integrate new therapeutic options with unique risk/benefits into an ingrained treatment paradigm that favors long-term safety and clinical experienceeven at the expense of more-robust efficacy.

Key Topics Covered:

1. Background

a) Publication Update

b) Report Contents and Features

c) Current Practice Guidelines

See the original post here:
Research and Markets: Key Findings from Treatment Algorithms: Multiple Sclerosis